Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand
Jul 23, 2021
AMSTERDAM, Netherlands and LOUISVILLE, Ky., July 23, 2021 /PRNewswire/ -- NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and US WorldMeds (USWM), a Kentucky-based specialty pharmaceutical company, today announced an exclusive licensing agreement by which Norgine will register and commercialise difluoromethylornithine, DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand. DFMO is a repurposed molecule investigated for use as